The “Throat Cancer Therapeutics Market by Type (Pharyngeal cancer and Laryngeal cancer) and Geography (North America, Europe, Asia, and Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the throat cancer therapeutics market size between 2021 and 2026 is USD 1.82 bn. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report.Key Market Dynamics:
- Market Driver: The increasing incidence of throat cancer is driving the growth of the market. Throat cancer cases have increased in recent years. Throat cancer is one of the most common types of cancer in many parts of the world, including Europe, Asia, and North America. Vendors are expected to introduce new therapies to cater to the huge unmet need for throat cancer therapeutics. In addition, awareness campaigns help in the early diagnosis of throat cancer indications. These factors are expected to result in the growth of the global throat cancer therapeutics market.
- Market Challenge: The preference for alternative treatment options will challenge the growth of the market. Most patients with throat cancer prefer surgery owing to its strong efficacy and quick recovery process. Moreover, advances in healthcare infrastructure have led to the advent of new surgical methods that ensure low risk. Hence, the increasing advances in treatment methods are expected to pose a threat to the growth of the global throat cancer therapeutics market.
Technavio provides key drivers, trends, and challenges that will shape the future of the market. View our FREE PDF Sample ReportMarket Segmentation
By type, the pharyngeal cancer segment will contribute the highest market share growth during the forecast period. The increasing risk factors of the indication are expected to benefit the market. Some of these risk factors include excessive use of tobacco products, heavy consumption of alcohol, exposure to high doses of radiation, and an increasing geriatric population. These factors are expected to drive the growth of this segment during the forecast period.
By geography, North America will be the leading region with 37% of the market’s growth during the forecast period. The US and Canada are the key countries for the throat cancer therapeutics market in North America. The growth of this region is driven by factors such as the strong prevalence of both pharyngeal cancer and laryngeal cancer in the US. Moreover, market growth in this region will be faster than the growth of the market in other regions.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Buy Now to access key information about segmentsSome Companies Mentioned
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol Myers Squibb Co.
- Celldex Therapeutics Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Hangzhou Adlai Nortye Biopharma Co. Ltd.
- Merck KGaA
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Spectrum Pharmaceuticals Inc.
- Accord Healthcare Ltd.
- Athenex Inc.
- Fresenius SE and Co. KGaA
- Hikma Pharmaceuticals Plc
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- WG Critical Care LLC
Want your report customized? Speak to an analyst and personalize your report according to your needs.Related Reports
Anaplastic Thyroid Cancer Drugs Market by Product and Geography – Forecast and Analysis 2022-2026
Non-melanoma Skin Cancer Market by Type and Geography – Forecast and Analysis 2022-2026
| Throat Cancer Therapeutics Market Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2021 |
| Forecast period | 2022-2026 |
| Growth momentum & CAGR | Accelerate at a CAGR of 6.7% |
| Market growth 2022-2026 | USD 1.82 billion |
| Market structure | Fragmented |
| YoY growth (%) | 5.11 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 37% |
| Key consumer countries | US, Canada, Hungary, Poland, and India |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Celldex Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hangzhou Adlai Nortye Biopharma Co. Ltd., Merck KGaA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Spectrum Pharmaceuticals Inc., Accord Healthcare Ltd., Athenex Inc., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and WG Critical Care LLC |
| Market Dynamics | Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse Health Care Market ReportsKey Topics Covered
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition – Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type – Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type – Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Pharyngeal cancer – Market size and forecast 2021-2026
- Exhibit 28: Chart on Pharyngeal cancer – Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Pharyngeal cancer – Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Pharyngeal cancer – Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Pharyngeal cancer – Year-over-year growth 2021-2026 (%)
- 5.4 Laryngeal cancer – Market size and forecast 2021-2026
- Exhibit 32: Chart on Laryngeal cancer – Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Laryngeal cancer – Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Laryngeal cancer – Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Laryngeal cancer – Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America – Market size and forecast 2021-2026
- Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
- 7.4 Europe – Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
- 7.5 Asia – Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
- 7.7 US – Market size and forecast 2021-2026
- Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
- 7.8 Hungary – Market size and forecast 2021-2026
- Exhibit 62: Chart on Hungary – Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Hungary – Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Hungary – Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Hungary – Year-over-year growth 2021-2026 (%)
- 7.9 India – Market size and forecast 2021-2026
- Exhibit 66: Chart on India – Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on India – Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on India – Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on India – Year-over-year growth 2021-2026 (%)
- 7.10 Poland – Market size and forecast 2021-2026
- Exhibit 70: Chart on Poland – Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Poland – Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Poland – Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Poland – Year-over-year growth 2021-2026 (%)
- 7.11 Canada – Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada – Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada – Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Amgen Inc.
- Exhibit 85: Amgen Inc. – Overview
- Exhibit 86: Amgen Inc. – Product / Service
- Exhibit 87: Amgen Inc. – Key offerings
- 10.4 AstraZeneca Plc
- Exhibit 88: AstraZeneca Plc – Overview
- Exhibit 89: AstraZeneca Plc – Product / Service
- Exhibit 90: AstraZeneca Plc – Key news
- Exhibit 91: AstraZeneca Plc – Key offerings
- 10.5 Bristol Myers Squibb Co.
- Exhibit 92: Bristol Myers Squibb Co. – Overview
- Exhibit 93: Bristol Myers Squibb Co. – Product / Service
- Exhibit 94: Bristol Myers Squibb Co. – Key offerings
- 10.6 Celldex Therapeutics Inc.
- Exhibit 95: Celldex Therapeutics Inc. – Overview
- Exhibit 96: Celldex Therapeutics Inc. – Product / Service
- Exhibit 97: Celldex Therapeutics Inc. – Key offerings
- 10.7 Eli Lilly and Co.
- Exhibit 98: Eli Lilly and Co. – Overview
- Exhibit 99: Eli Lilly and Co. – Product / Service
- Exhibit 100: Eli Lilly and Co. – Key offerings
- 10.8 F. Hoffmann La Roche Ltd.
- Exhibit 101: F. Hoffmann La Roche Ltd. – Overview
- Exhibit 102: F. Hoffmann La Roche Ltd. – Business segments
- Exhibit 103: F. Hoffmann La Roche Ltd. – Key news
- Exhibit 104: F. Hoffmann La Roche Ltd. – Key offerings
- Exhibit 105: F. Hoffmann La Roche Ltd. – Segment focus
- 10.9 Hangzhou Adlai Nortye Biopharma Co. Ltd.
- Exhibit 106: Hangzhou Adlai Nortye Biopharma Co. Ltd. – Overview
- Exhibit 107: Hangzhou Adlai Nortye Biopharma Co. Ltd. – Product / Service
- Exhibit 108: Hangzhou Adlai Nortye Biopharma Co. Ltd. – Key offerings
- 10.10 Merck KGaA
- Exhibit 109: Merck KGaA – Overview
- Exhibit 110: Merck KGaA – Business segments
- Exhibit 111: Merck KGaA – Key news
- Exhibit 112: Merck KGaA – Key offerings
- Exhibit 113: Merck KGaA – Segment focus
- 10.11 Pfizer Inc.
- Exhibit 114: Pfizer Inc. – Overview
- Exhibit 115: Pfizer Inc. – Product / Service
- Exhibit 116: Pfizer Inc. – Key news
- Exhibit 117: Pfizer Inc. – Key offerings
- 10.12 Regeneron Pharmaceuticals Inc.
- Exhibit 118: Regeneron Pharmaceuticals Inc. – Overview
- Exhibit 119: Regeneron Pharmaceuticals Inc. – Product / Service
- Exhibit 120: Regeneron Pharmaceuticals Inc. – Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 121: Inclusions checklist
- Exhibit 122: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 123: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 124: Research methodology
- Exhibit 125: Validation techniques employed for market sizing
- Exhibit 126: Information sources
- 11.5 List of abbreviations
- Exhibit 127: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/
SOURCE Technavio